Aisling Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Aisling Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$367K	Hold	88,607	–	–	0.08%	13
2025 Q4	$257K	Hold	88,607	–	–	0.05%	13
2025 Q3	$244K	Hold	88,607	–	–	0.05%	14
2025 Q2	$212K	Hold	88,607	–	–	0.06%	13
2025 Q1	$381K	Hold	88,607	–	–	0.13%	13
2024 Q4	$762K	Sell	88,607 -1	-0%	-$15	0.27%	14
2024 Q3	$1.51M	Hold	88,608	–	–	0.58%	13
2024 Q2	$1.34M	Hold	88,608	–	–	0.58%	13
2024 Q1	$1.47M	Hold	88,608	–	–	0.5%	11
2023 Q4	$1.42M	Hold	88,608	–	–	0.42%	12
2023 Q3	$6.74M	Hold	88,608	–	–	2.78%	7
2023 Q2	$5.81M	Hold	88,608	–	–	2.85%	6
2023 Q1	$5.3M	Hold	88,608	–	–	2.55%	7
2022 Q4	$2.06M	Hold	88,608	–	–	1.36%	10
2022 Q3	$2.97M	Hold	88,608	–	–	1.97%	10
2022 Q2	$2.35M	Hold	88,608	–	–	1.68%	11
2022 Q1	$2.6M	Hold	88,608	–	–	1.41%	13
2021 Q4	$7.58M	Hold	88,608	–	–	2.67%	11
2021 Q3	$6.6M	Hold	88,608	–	–	1.32%	14
2021 Q2	$8.27M	Buy	+88,608	New	+$9.88M	1.32%	16

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aisling Capital Management's OKUR Position: Q1 2026 in Review

Aisling Capital Management held its OnKure Therapeutics (OKUR) position steady in Q1 2026 at 88,607 shares worth $367K. The position accounts for 0.08% of the portfolio, ranked #13.

Aisling Capital Management first reported a position in OKUR in Q2 2021 and has held it in 20 quarters since. The position peaked at $8.27M in Q2 2021. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

Aisling Capital Management held 88,607 shares of OnKure Therapeutics worth $367K as of Q1 2026.
Aisling Capital Management left its OnKure Therapeutics share count unchanged in Q1 2026.
OnKure Therapeutics made up 0.08% of Aisling Capital Management's portfolio in Q1 2026, its #13 holding.
Aisling Capital Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 20 quarters since.
Aisling Capital Management's OnKure Therapeutics position peaked at $8.27M in Q2 2021.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Aisling Capital Management's 13F filing for Q1 2026, filed 5 May 2026.